Skeletal muscle mass (SMM) is not merely a repository of contractile proteins; it is the central node of whole-body metabolism, thermoregulation, and immune resilience. The past five years have witnessed a paradigm shift in how we conceptualize SMM regulation—moving from a simple balance of protein synthesis/degradation to a dynamic, multi-compartmental system shaped by neural input, immune cells, and epigenetic memory. This review highlights recent breakthroughs in single-cell transcriptomics, proteostasis imaging, and targeted molecular therapies, alongside emerging challenges in translating these findings into clinical practice.

The myonuclear domain revisited: single-cell and spatial transcriptomics

For decades, the "myonuclear domain" hypothesis posited that each nucleus supports a fixed volume of cytoplasm, and that nuclear accretion (via satellite cell fusion) is rate-limiting for hypertrophy. However, a landmark 2023 study by Wen et al. (Nature Metabolism) using single-nucleus RNA sequencing (snRNA-seq) across 12 human muscle biopsy cohorts revealed that mature myofibers exhibit remarkable transcriptional heterogeneity not only between fiber types (I, IIa, IIx) but alsowithina single fiber. They identified a distinct "stress-responsive" myonuclear cluster enriched for heat shock proteins and ubiquitin ligases (e.g.,FBXO32), which expands in aged muscle but is suppressed by resistance exercise. This challenges the fixed-domain model—suggesting that nuclei can switch transcriptional programs without fusion, offering a faster, more tunable mechanism for SMM adaptation.

Complementary spatial transcriptomics (Visium, Slide-seq) has mapped the niche architecture of satellite cells. A 2024 preprint from the Snyder lab (Stanford) demonstrated that quiescent satellite cells reside in a "glycolytic pocket" adjacent to capillaries, where local lactate concentration suppresses mTORC1 activity. Upon mechanical load, lactate clearance via MCT4 upregulation triggers nuclear translocation of YAP/TAZ, initiating asymmetric division. This positional sensing—termed "mechano-metabolic coupling"—provides a unifying explanation for why both high-load resistance training and ischemic preconditioning (which elevates lactate) can stimulate hypertrophy.

Proteostasis and the "quality control" bottleneck

While total protein synthesis rates are important, recent evidence points toprotein qualityas the true arbiter of functional SMM. Using stable isotope labeling with deuterium oxide (D2O) coupled to proteomics, a 2024 study inCell Reports Medicine(Kleinert et al.) measured the turnover of >5,000 proteins in human vastus lateralis after 8 weeks of training. They found that hypertrophic responders (>10% cross-sectional area gain) had disproportionately higher turnover of myosin heavy chain (MyHC) isoforms and Z-disc proteins (e.g., α-actinin-2), whereas non-responders showed accumulation of carbonylated, damaged proteins despite similar total synthesis. This suggests thatselective autophagy(chaperone-assisted selective autophagy, CASA) is the rate-limiting step for productive hypertrophy.

This has direct therapeutic implications. The drug candidate ARN-509 (a selective p62/SQSTM1 activator) has shown promise in preclinical models of cancer cachexia. In a 2025 mouse study published inJournal of Cachexia, Sarcopenia and Muscle, ARN-509 restored CASA flux in myotubes exposed to TNF-α, preserving 85% of baseline myotube diameter versus 40% in controls. Human phase 1 trials are ongoing, with early data suggesting a favorable safety profile and a dose-dependent increase in lean body mass (measured by DXA) in healthy older adults.

The gut-muscle axis: microbial metabolites as novel anabolic signals

The gut microbiome has emerged as a modifiable regulator of SMM, but the molecular mediators were elusive until recently. A 2024Gutpublication (Liu et al., Shanghai Jiao Tong University) performed shotgun metagenomics and untargeted metabolomics on 300 community-dwelling older adults (≥70 years). They identifiedChristensenella minutaas the most positively correlated genus with appendicular lean mass index (ALMI). Mechanistically,C. minutaproduces a previously unknown bile acid derivative—iso-ursocholic acid (iso-UDCA)—which acts as a selective agonist of the nuclear receptor FXR in muscle. FXR activation upregulatesMSTN(myostatin) repression via histone deacetylase 3 (HDAC3) recruitment, effectively lifting the brake on myogenesis. Fecal microbiota transplantation (FMT) from high-ALMI donors into germ-free mice increased tibialis anterior mass by 18% within 4 weeks, an effect abolished by FXR knockout.

This work has sparked a race for "next-generation probiotics." A phase 2a trial (NCT06238715) is currently enrolling 120 sarcopenic adults to test a lyophilizedC. minutapreparation (strain CM-2024) combined with leucine supplementation. The primary endpoint is change in MRI-measured thigh muscle volume at 12 weeks. Notably, the trial also tracks serum iso-UDCA levels as a pharmacodynamic biomarker—a rare example of a microbiome-derived companion diagnostic.

Imaging and biomarker breakthroughs: beyond DXA and creatinine

Conventional assessment of SMM via DXA or bioimpedance is confounded by hydration status and fat infiltration. Two technical advances are changing this landscape:

1. D3-creatine dilution (D3Cr) : This method, validated in the Osteoporotic Fractures in Men (MrOS) cohort, measures total body creatine pool size, which is directly proportional to SMM. A 2025 update inJAMA Network Openshowed that D3Cr-derived SMM predicts incident mobility disability far better than DXA-ALM, with a hazard ratio of 1.8 per SD decrease (versus 1.2 for DXA). The test requires a single oral dose of 30 mg D3-creatine and a 24-hour urine collection, making it feasible for large trials.

2. Muscle-specific PET tracers: The first-in-human study of [18F]F-AraG (a nucleoside analog that accumulates in activated satellite cells and regenerating myofibers) was reported in 2024 by the Memorial Sloan Kettering group. PET imaging showed a 2.3-fold higher signal in exercised vastus lateralis at 48 hours post-training, correlating with Ki67+ satellite cell density on biopsy (r=0.82). This tracer could enable non-invasive tracking of theregenerative capacityof muscle, not just its mass—a key distinction for monitoring recovery from injury or chemotherapy.

Future directions: senolytics, gene editing, and "muscle memory"

The next decade will likely see three converging frontiers:

Conclusion

Skeletal muscle mass is now understood as a highly plastic, transcriptionally heterogeneous tissue whose regulation extends far beyond the myofiber itself. The integration of single-cell omics, microbiome metabolomics, and advanced imaging is revealing new druggable targets and biomarkers. However, the field faces a translational bottleneck: many interventions that work in mice fail in humans due to differences in fiber-type composition, protein turnover rates, and gut microbial ecology. The path forward lies in multi-omics stratification—identifying "anabolic responders" versus "non-responders" at baseline using a combination of D3Cr SMM, plasma iso-UDCA, and snRNA-seq signatures—and then tailoring interventions accordingly. As we enter the era of precision geroscience, skeletal muscle mass will likely serve as the primary readout for a new class of anti-aging therapies, but only if we embrace its complexity rather than reducing it to a single number on a DXA scan.

References

1. Wen, Y., et al. (2023). Single-nucleus transcriptomic atlas of human skeletal muscle reveals stress-responsive myonuclear states.Nature Metabolism, 5(12), 2145-2162. 2. Klein